FREAMINE HBC- isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, and sodium bisulfite injection, solution
B. Braun Medical Inc.

--------

6.9% FreAmine HBC®
(Amino Acid Injection)

Protect from light until use.

DESCRIPTION

6.9% FreAmine HBC® (Amino Acid Injection) is a sterile, nonpyrogenic, hypertonic solution containing crystalline amino acids. A 750 mL partial fill unit provides a total of 7.3 g of nitrogen in 50 g of amino acids equal to 46 grams of protein equivalent. All amino acids designated USP are the "L"-isomer with the exception of Glycine USP, which does not have an isomer.

Each 100 mL contains:

**Essential Amino Acids**

- Isoleucine USP ............................................................ 0.76 g
- Leucine USP ............................................................... 1.37 g
- Lysine ......................................................................... 0.41 g
  (added as Lysine Acetate USP .................. 0.58 g)
- Methionine USP .......................................................... 0.25 g
- Phenylalanine USP ....................................................... 0.32 g
- Threonine USP ............................................................ 0.20 g
- Tryptophan USP ......................................................... 0.09 g
- Valine USP ................................................................. 0.88 g

**Nonessential Amino Acids**

- Alanine USP ............................................................... 0.40 g
- Arginine USP .............................................................. 0.58 g
- Histidine USP .............................................................. 0.16 g
- Proline USP ............................................................... 0.63 g
- Serine USP ................................................................. 0.33 g
- Glycine USP ............................................................... 0.33 g
- Cysteine .................................................................... <0.014 g
  (as Cysteine HCl•H₂O USP ...................... <0.020 g)
- Sodium Bisulfite (as an antioxidant) ............... <0.10 g
- Water for Injection USP .............................................. qs

pH adjusted with Glacial Acetic Acid USP
pH: 6.5 (6.0 – 7.0)
Calculated Osmolarity: 620 mOsmol/liter
Concentration of Electrolytes (mEq/liter): Sodium 10; Chloride <3 Acetate Approx. 59.3 (provided as acetic acid and lysine acetate)

**CLINICAL PHARMACOLOGY**

6.9% FreAmine HBC® solution provides a mixture of biologically utilizable essential and nonessential crystalline amino acids in concentrated form for protein synthesis. 6.9% FreAmine HBC® contains a high concentration of the branched chain amino acids isoleucine, leucine, and valine relative to other general purpose amino acid injections. This amino acid solution, appropriately mixed with a concentrated calorie source such as hypertonic dextrose, with or without fat emulsion, and supplemented with electrolytes, vitamins, and minerals, provides total parenteral nutrition for the severely compromised patient. 6.9% FreAmine HBC® solution may also be administered peripherally with minimal caloric supplementation in order to conserve lean body mass in the well-nourished, mildly catabolic patient.

The concentration of branched chain amino acids in 6.9% FreAmine HBC® has been increased because these amino acids have been reported to be especially active metabolically in the compromised patient.

It is thought that the acetate from lysine acetate and acetic acid, under the condition of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available.

The amounts of sodium and chloride present are not of clinical significance.

**INDICATIONS AND USAGE**

Parenteral nutrition with 6.9% FreAmine HBC® (Amino Acid Injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) nitrogen homeostasis is substantially impaired as with severe trauma or sepsis. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. See DO dosage and ADMINISTRATION.

**Central Venous Nutrition**

Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term parenteral nutrition.

**Peripheral Parenteral Nutrition**

For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions with minimal caloric supplementation may be infused by peripheral vein, supplemented, if desired, with fat emulsion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).

**CONTRAINDICATIONS**

6.9% FreAmine HBC® is contraindicated in patients with anuria, hepatic coma, inborn errors of amino acid metabolism, especially those involving branched chain amino acid metabolism such as Maple Syrup Urine Disease and Isovaleric Acidemia, or hypersensitivity to one or more amino acids present in the solution.
WARNINGS

This product contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Safe and effective use of central venous nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring of central venous nutrition. Laboratory tests should include measurement of blood sugar, electrolyte, and serum protein concentrations; kidney and liver function tests; and evaluation of acid-base balance and fluid balance. Other laboratory tests may be suggested by the patient's condition.

The intravenous administration of these solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the solute concentration of the solution infused. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the concentration of the solution.

Administration of amino acids in the presence of impaired renal function or gastrointestinal bleeding may augment an already elevated blood urea nitrogen. Patients with azotemia from any cause should not be infused with amino acids without regard to total nitrogen intake.

Administration of amino acid solutions that have not been specifically formulated to treat patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma.

Conservative doses of amino acids should be given, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient's clinical status reevaluated.

PRECAUTIONS

General

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements.

Strongly hypertonic nutrient solutions should be administered through an indwelling intravenous catheter with the tip located in the superior vena cava.

Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency.

In patients with myocardial infarct, infusion of amino acids should always be accompanied by dextrose, since in anoxia, free fatty acids cannot be utilized by the myocardium, and energy must be produced.
anaerobically from glycogen or glucose.

Special care must be taken when giving hypertonic dextrose to a diabetic or prediabetic patient. To prevent severe hyperglycemia in such patients, insulin may be required.

Administration of glucose at a rate exceeding the patient's utilization may lead to hyperglycemia, coma, and death.

Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrate.

After appropriate dilution, if 6.9% FreAmine HBC® (Amino Acid Injection) is to be administered by peripheral vein, care should be taken to assure proper placement of the infusion device within the lumen of the vein. The venipuncture site should be inspected frequently for signs of infiltration. If venous thrombosis or phlebitis occurs, discontinue infusions or change infusion site and initiate appropriate treatment.

Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation.

Metabolic acidosis can be prevented or readily controlled by adding a portion of the cations in the electrolyte mixture as acetate salts and in the case of hyperchloremic acidosis, by keeping the total chloride content of the infusate to a minimum. 6.9% FreAmine HBC® contains less than 3 mEq chloride per liter.

6.9% FreAmine HBC® contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. To assure adequate intake, serum levels should be monitored frequently.

When the solution is subjected to changes in temperature, crystallization of amino acids may occur. If crystals appear redissolve by addition of the dextrose solution followed by gentle agitation. Alternatively, redissolve crystals by warming the unopened unit to 40°C followed by gentle agitation for about one minute. If the amino acids do not completely redissolve, the bottle must be rejected.

To minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration.

Use only if solution is clear and vacuum is present.

Drug product contains no more than 25 µg/L of aluminum.

**Laboratory Tests**

Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring of central venous nutrition.

Laboratory tests should include measurement of blood sugar, electrolyte, and serum protein concentrations; kidney and liver function tests; and evaluation of acid-base balance and fluid balance. Other laboratory tests may be suggested by the patient's condition.

**Drug Interactions**

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

No in vitro or in vivo carcinogenesis, mutagenesis, or fertility studies have been conducted with 6.9% FreAmine HBC® (Amino Acid Injection).
Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with 6.9% FreAmine HBC® (Amino Acid Injection). It is also not known whether 6.9% FreAmine HBC® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 6.9% FreAmine HBC® should be given to a pregnant woman only if clearly needed.

Labor and Delivery

Information is unknown.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 6.9% FreAmine HBC® (Amino Acid Injection) is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of amino acid injections in pediatric patients have not been established by adequate and well-controlled studies. However, the use of amino acid injections in pediatric patients as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance is well established in the medical literature. See WARNINGS and DOSAGE AND ADMINISTRATION.

Geriatric Use

Clinical studies of 6.9% FreAmine HBC® (Amino Acid Injection) did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. See WARNINGS.

Special Precautions for Central Venous Nutrition

Administration by central venous catheter should be used only by those familiar with this technique and its complications.

Central venous nutrition may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure including solution preparation, administration, and patient monitoring. It is essential that a carefully prepared protocol, based on current medical practices, be followed, preferably by an experienced team.

Although a detailed discussion of the complications of central venous nutrition is beyond the scope of this insert, the following summary lists those based on current literature:

Technical

The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion as well as recognition and treatment of complications. For details of techniques and placement sites, consult the medical literature. X-ray is the
best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arterio-venous fistula, phlebitis, thrombosis, and air and catheter embolus.

Septic

The constant risk of sepsis is present during central venous nutrition. Since contaminated solutions and infusion catheters are potential sources of infection, it is imperative that the preparation of parenteral nutrition solutions and the placement and care of catheters be accomplished under controlled aseptic conditions.

Solutions should ideally be prepared in the hospital pharmacy in a laminar flow hood. The key factor in their preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and subsequent admixtures.

Parenteral nutrition solutions should be used promptly after mixing. Any storage should be under refrigeration for as brief a time as possible. Administration time for a single bottle and set should never exceed 24 hours.

Consult the medical literature for a discussion of the management of sepsis during central venous nutrition. In brief, typical management includes replacing the solution being administered with a fresh container and set, and culturing the remaining contents for bacterial or fungal contamination. If sepsis persists and another source of infection is not identified, the catheter is removed, the proximal tip cultured, and a new catheter reinserted when the fever has subsided. Non-specific, prophylactic antibiotic treatment is not recommended. Clinical experience indicates that the catheter is likely to be the prime source of infection as opposed to aseptically prepared and properly stored solutions.

Metabolic

The following metabolic complications have been reported: metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia and glycosuria, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, hypo-and hypervitaminosis, electrolyte imbalances, and hyperammonemia in pediatric patients. Frequent clinical evaluation and laboratory determinations are necessary, especially during the first few days of central venous nutrition, to prevent or minimize these complications.

ADVERSE REACTIONS

See "WARNINGS" and "Special Precautions for Central Venous Nutrition".

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Local reactions of the infusion site, consisting of a warm sensation, erythema, phlebitis and thrombosis, have been reported with peripheral amino acid infusions, especially if other substances are also administered through the same site.

Generalized flushing, fever and nausea have been reported during peripheral administration of amino acids.

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

If electrolyte supplementation is required during peripheral infusion, it is recommended that additives be administered throughout the day in order to avoid possible venous irritation. Irritating additive medications may require injection at another site and should not be added directly to the amino acid infusate.
Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

**OVERDOSAGE**

In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

**DOSAGE AND ADMINISTRATION**

The total daily dose of 6.9% FreAmine HBC® (Amino Acid Injection) depends on daily protein requirements and on the patient's metabolic and clinical response. The determination of nitrogen balance and accurate daily body weights, corrected for fluid balance, are probably the best means of assessing individual protein requirements.

While Recommended Dietary Allowances of protein are approximately 0.8 g/kg of body weight for a healthy adult, it must be recognized that protein as well as caloric requirements in traumatized or malnourished patients may be substantially increased. Daily amino acid doses of approximately 1.5 g/kg of body weight for adults with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Higher doses may be required in severely catabolic states. Such higher doses must be accompanied by frequent laboratory evaluation. Fat emulsion may be supplied to help meet energy requirements.

Fat emulsion coadministration should be considered when prolonged (more than 5 days) parenteral nutrition is required in order to prevent essential fatty acid deficiency (E.F.A.D.). Serum lipids should be monitored for evidence of E.F.A.D. in patients maintained on fat free TPN.

The provision of sufficient intracellular electrolytes, principally potassium, magnesium, and phosphate, is also required for optimum utilization of amino acids. Approximately 60 – 180 mEq of potassium, 10 – 30 mEq of magnesium, and 20 – 80 mEq of phosphate per day appear necessary to achieve optimum metabolic response. In addition, sufficient quantities of the major extracellular electrolytes (sodium, calcium, and chloride) must be given. In patients with hyperchloremic or other metabolic acidoses, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate precursor. The electrolyte content of 6.9% FreAmine HBC® must be considered when calculating daily electrolyte intake. Serum electrolytes, including magnesium and phosphorus, should be monitored frequently.

If a patient's nutritional intake is primarily parenteral, vitamins, especially the water soluble vitamins, and trace elements should also be provided.

**Central Venous Nutrition**

For severely catabolic, depleted patients or those requiring long-term total parenteral nutrition, central venous nutrition should be considered. Total parenteral nutrition may be started with infusates containing lower concentrations of dextrose; dextrose content may be gradually increased to estimated caloric needs as the patient's glucose tolerance increases.

In adults, strongly hypertonic mixtures of amino acids and dextrose may be safely administered only by continuous infusion through a central venous catheter with the tip located in the vena cava. A mixture of 750 mL 6.9% FreAmine HBC® (Amino Acid Injection) solution, and 250 mL 70% Dextrose, supplemented with electrolytes, and vitamins may be administered over an 8-hour period. If administration rate should fall behind schedule, no attempt to "catch up" to planned intake should be made. In addition to meeting protein needs, the administration rate is also governed, especially during the first few days of therapy by the patient's glucose tolerance. Daily intake of amino acids and dextrose
should be increased gradually to the maximum required dose as indicated by frequent determination of urine and blood sugar levels. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% Dextrose should be administered when hypertonic dextrose infusions are abruptly discontinued.

**Peripheral Parenteral Nutrition**

For moderately catabolic, depleted patients requiring parenteral nutrition in whom the central venous route is not indicated, diluted 6.9% FreAmine HBC® with minimal caloric supplementation may be infused by peripheral vein, supplemented, if desired, with fat emulsion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).

Fat provides approximately 9 kcal per gram and parenteral fat emulsion may be administered along with amino acid-dextrose solutions through a Y-type administration set to supplement caloric intake. Fat, however, should not provide more than 60% of the total caloric intake.

**Pediatric Use**

Use of 6.9% FreAmine HBC® in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day. Two to three g/kg of body weight for infants with adequate calories are generally sufficient to satisfy protein needs and promote positive nitrogen balance. Solutions administered by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L). See **WARNINGS** and **PRECAUTIONS, Pediatric Use**.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

6.9% FreAmine HBC® may be admixed with solutions which contain phosphate or which have been supplemented with phosphate. The presence of calcium and magnesium ions in an additive solution should be considered when phosphate is also present, in order to avoid precipitation.

Care must be taken to avoid incompatible admixtures. Consult with pharmacist.

**HOW SUPPLIED**

6.9% FreAmine HBC® is supplied sterile and nonpyrogenic in 750 mL partial-fill 1000 mL glass intravenous infusion containers with solid stoppers, packaged 6 per case.

<table>
<thead>
<tr>
<th>NDC</th>
<th>REF</th>
<th>Container Size</th>
<th>Fill</th>
</tr>
</thead>
<tbody>
<tr>
<td>0264-9350-55</td>
<td>S9350-58SS</td>
<td>1000 mL</td>
<td>750 mL</td>
</tr>
</tbody>
</table>

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

Protect from light until use.

**Rx only**

Revised: November 2013

FreAmine HBC is a registered trademark of B. Braun Medical Inc.
Directions for Use of B. Braun Glass Containers with Solid Stoppers

Designed for use with a vented set. Use 18 to 22 gauge needle size for admixing or withdrawing solutions from the glass bottle.

Before use, perform the following checks:

1. Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.
2. Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter; check the bottle for cracks or other damage. In checking for cracks, do not be confused by normal surface marks and seams on bottom and sides of bottle. These are not flaws. Look for bright reflections that have depth and penetrate into the wall of the bottle. Reject any such bottle.
3. To remove the outer closure, lift the tear tab and pull up, over, and down until it is below the stopper (see Figure 1). Use a circular pulling motion on the tab until it breaks away.
4. Grasp and remove the metal disk, exercising caution not to touch the exposed sterile stopper surface.

**Warning:** Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.
5. When adding medication to the container prior to administration, swab the target area of the rubber stopper, inject medication and mix thoroughly by gentle agitation.
6. Refer to Directions for Use of the set being used. Insert the set spike into the bottle through the target area of the rubber stopper. Allow the fluid to flow and remove air from the tubing before administration begins. Hang the container.
7. After admixture and during administration, re-inspect the solution frequently. If any evidence of solution contamination or instability is found or if the patient exhibits any signs of fever, chills or other reactions not readily explainable, discontinue administration immediately and notify the physician.
8. Spiking, additions, or transfers should be made immediately after exposing the sterile stopper surface. Check for vacuum at first puncture of stopper. Admixture by needle or syringe should be made through the target area of the rubber stopper; contents should be drawn by vacuum into the bottle. Admixture by spiked vial should also be through the target area of the rubber stopper (see Figure 2). If contents of initial addition are not drawn into the bottle, vacuum is not present and the unit should be discarded. Each addition/transfer will reduce the vacuum remaining in the bottle.
9. If the first puncture of the stopper is the administration set spike, insert the spike fully into the target area of the rubber stopper and promptly invert the bottle. Verify vacuum by observing rising air bubbles. Do not use the bottle if vacuum is not present.

10. If admixture or set insertion is not performed immediately following removal of protective metal disk, swab stopper surface.

   CAUTION: Large partial fill containers (one liter or larger) have high vacuum to facilitate large additions or transfers. This creates an implosion hazard and requires special care in use and handling.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
1-800-227-2862
www.bbraun.com
Made in USA
Y36-002-854 LD-446-1

PRINCIPAL DISPLAY PANEL - 750 mL Container Label

750 mL
NDC 0264-9350-55
S9350-58SS

6.9% FreAmine HBC®
(Amino Acid Injection)

Partial Fill Container

Protect from light until use.

Each 100 mL contains:

**Essential Amino Acids** - Isoleucine USP 0.76 g
Leucine USP 1.37 g; Lysine 0.41 g (added as Lysine Acetate USP 0.58 g)
Methionine USP 0.25 g; Phenylalanine USP 0.32 g
Threonine USP 0.20 g; Tryptophan USP 0.09 g
Valine USP 0.88 g
**Nonessential Amino Acids** - Alanine USP 0.40 g
Arginine USP 0.58 g; Histidine USP 0.16 g
Proline USP 0.63 g; Serine USP 0.33 g
Glycine USP 0.33 g; Cysteine <0.014 g (as Cysteine HCl•H₂O USP <0.020 g)
Sodium Bisulfite (antioxidant) <0.10 g
Water for Injection USP qs
pH adjusted with Glacial Acetic Acid USP
pH: 6.5 (6.0-7.0)
Calculated Osmolarity: 620 mOsmol/liter

**Electrolytes (mEq/liter):** Sodium 10; Chloride <3
Acetate Approx. 59.3 (see Package Insert)

Sterile, nonpyrogenic. Single dose container.

For intravenous use only. Use only if solution is clear and vacuum is present.

If crystals appear, see unit carton for instructions.

Recommended Storage:
See Package Insert.

Rx only

FreAmine HBC is a registered trademark of B. Braun Medical Inc.

**B. Braun Medical Inc.**
Irvine, CA 92614-5895 USA

Made in USA
Y37-002-284 LD-356-1
6.9% FreAmine® HBC
(Amino Acid Injection)

Partial Fill Container

Protect from light until use.

Each 100 mL contains:

**Essential Amino Acids**
- Isoleucine USP 0.76 g; Leucine USP 1.37 g
- Lysine 0.41 g (added as Lysine Acetate USP 0.58 g)
- Methionine USP 0.25 g; Phenylalanine USP 0.32 g
- Threonine USP 0.20 g; Tryptophan USP 0.09 g
- Valine USP 0.88 g

**Nonessential Amino Acids**
- Alanine USP 0.40 g; Arginine USP 0.58 g
- Histidine USP 0.16 g; Proline USP 0.63 g
- Serine USP 0.33 g; Glycine USP 0.33 g
- Cysteine <0.014 g (as Cysteine HCl•H₂O USP <0.020 g)

Sodium Bisulfite (antioxidant) <0.10 g
Water for Injection USP qs

pH adjusted with Glacial Acetic Acid USP
pH: 6.5 (6.0-7.0)
Calculated Osmolarity: 620 mOsmol/liter

**Electrolytes (mEq/liter):**
- Sodium 10; Chloride <3

Acetate Approx. 59.3 (see Package Insert)

See adjacent panel for further product information.

Sterile, nonpyrogenic. Single dose container.

For intravenous use only.
Use only if solution is clear and vacuum is present.

If crystals appear redissolve by addition of the dextrose solution followed by gentle agitation. Alternatively, redissolve crystals by warming the unopened unit to 40°C followed by gentle agitation for about one minute.

Recommended Storage:
Room temperature (25°C). Avoid excessive heat.
Protect from freezing. See Package Insert.

Rx only

FreAmine is a registered trademark of B. Braun Medical Inc.

**B. Braun Medical Inc.**
Irvine, CA USA 92614-5895
X12-001-420
**FREAMINE HBC**

Isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, and sodium bisulfite injection, solution

<table>
<thead>
<tr>
<th>Product Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
<td>HUMAN PRESCRIPTION DRUG</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>INTRAVENOUS</td>
</tr>
<tr>
<td><strong>Item Code (Source)</strong></td>
<td>NDC:0264-9350</td>
</tr>
</tbody>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISOLEUCINE (UNII: 04Y7590D77)</td>
<td>ISOLEUCINE</td>
<td>0.76 g in 100 mL</td>
</tr>
<tr>
<td>LEUCINE (UNII: GMW67QNF9C)</td>
<td>LEUCINE</td>
<td>1.37 g in 100 mL</td>
</tr>
<tr>
<td>LYSINE ACETATE (UNII: TTL6G7L8WZ)</td>
<td>LYSINE</td>
<td>0.41 g in 100 mL</td>
</tr>
<tr>
<td>METHIONINE (UNII: AE28F7PNPL)</td>
<td>METHIONINE</td>
<td>0.25 g in 100 mL</td>
</tr>
<tr>
<td>PHENYLALANINE (UNII: 47E5O17Y3R)</td>
<td>PHENYLALANINE</td>
<td>0.32 g in 100 mL</td>
</tr>
<tr>
<td>THREONINE (UNII: 2ZD004190S)</td>
<td>THREONINE</td>
<td>0.2 g in 100 mL</td>
</tr>
<tr>
<td>TRYPTOPHAN (UNII: 8DUHIN11BX)</td>
<td>TRYPTOPHAN</td>
<td>0.09 g in 100 mL</td>
</tr>
<tr>
<td>VALINE (UNII: HG18B9YRS7)</td>
<td>VALINE</td>
<td>0.88 g in 100 mL</td>
</tr>
<tr>
<td>ALANINE (UNII: OF5P57N2ZX)</td>
<td>ALANINE</td>
<td>0.4 g in 100 mL</td>
</tr>
<tr>
<td>ARGinine (UNII: 94ZLA3W45F)</td>
<td>ARGinine</td>
<td>0.58 g in 100 mL</td>
</tr>
<tr>
<td>HISTIDINE (UNII: 4QD397987E)</td>
<td>HISTIDINE</td>
<td>0.16 g in 100 mL</td>
</tr>
<tr>
<td>PROLINE (UNII: 9DLQ4CIU6V)</td>
<td>PROLINE</td>
<td>0.63 g in 100 mL</td>
</tr>
<tr>
<td>SERINE (UNII: 452VLY9402)</td>
<td>SERINE</td>
<td>0.33 g in 100 mL</td>
</tr>
<tr>
<td>GLYCINE (UNII: TE7660XO1C)</td>
<td>GLYCINE</td>
<td>0.33 g in 100 mL</td>
</tr>
<tr>
<td>CYSTEINE HYDROCHLORIDE (UNII: ZT934NOXW4)</td>
<td>CYSTEINE</td>
<td>0.014 g in 100 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>SODIUM BISULFITE (UNII: TZX5469Z6I)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0264-9350-55</td>
<td>6 in 1 CASE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>750 mL in 1 CONTAINER</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA016822</td>
<td>09/24/1971</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - B. Braun Medical Inc. (002397347)